
Keywords: BB; bevacizumab-bevacizumab; BP; bevacizumab followed by panitumumab; CA9; carbonic anhydrase 9; CRC; colorectal cancer; DEGs; differentially expressed genes; EGFR; epidermal growth factor receptor; EPHA2; ephrin type-A receptor 2; FASN; fatty acid syntha